Navigation Links
Improved detection of frontotemporal degeneration may aid clinical trial efforts
Date:3/15/2013

SAN DIEGO - A series of studies demonstrate improved detection of the second most common form of dementia, providing diagnostic specificity that clears the way for refined clinical trials testing targeted treatments. The new research is being presented by experts from the Perelman School of Medicine at the University of Pennsylvania at the American Academy of Neurology's 65th Annual Meeting in San Diego March 16-23, 2013.

Frontotemporal degeneration, the most common dementia in people under 60, can be hereditary or sporadic in nature and caused by one of two different mutated proteins (tau or TDP-43). The disease results in damage to the anterior temporal and/or frontal lobes of the brain. As the disease progresses, it becomes increasingly difficult for people to plan or organize activities, behave appropriately in social or work settings, interact with others, and care for oneself, resulting in increasing dependency.

In one study, the team confirmed that a novel multimodal imaging approach was more accurate (88 percent) than using either MRI (72 percent) or DTI (81 percent) alone to detect FTD versus Alzheimer's disease. The two imaging techniques integrate measures of white matter and grey matter, providing a statistically powerful method for predicting underlying pathology in order to screen patients for clinical trials.

"We are moving forward on our biomarker work to optimize our ability to identify the specific cause of an individual's difficulties during life, said senior author Murray Grossman, MD, EdD, professor of Neurology and director of the Penn FTLD Center. "We use a novel multi-modality approach involving behavioral, imaging and biofluid biomarker measures."

In a second study, researchers found that a brief series of neuropsychological tests of memory, word generation and conceptual flexibility (needed for creative problem-solving) helped differentiate people with very mild behavioral variant FTD (bvFTD) and those with mild cognitive impairment (MCI). The combination of tests correctly classified 85.7 percent of bvFTD cases and 83.3 percent of MCI cases at early stages of disease.

"This is particularly important because treatment trials with disease-modifying agents are emerging, often based on animal studies, yet we still don't have all the tools we need to identify who is most appropriate to participate in one of these trials. Moreover, we can use this information we ascertain to help determine who is responding to a treatment in a clinical trial."

The third study being presented at the meeting showed that hereditary forms of FTD appear to have more rapid cognitive decline and differing tau profiles compared with sporadic forms of the disease. For clinical trials testing whether a drug can delay damage caused by tau, any known differences in the speed of disease progression could interfere with trial results.


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-200-2312
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Improved Stem Cell Line May Avoid Tumor Risk: Study
2. Staging and risk stratification of thyroid cancer improved with SPECT/CT
3. Reported increase in older adult fall deaths due to improved coding
4. Ketamine improved bipolar depression within minutes
5. Exercise program improved health of lung transplant patients and cut cardiovascular risk
6. GMCSF treatment associated with improved cognition in cancer patients
7. PaleoMeal Organic Whey Protein Formula Improved According to Rockwell Nutrition
8. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
9. Expanding Medicaid to low-income adults leads to improved health, fewer deaths
10. Is Improved Vaccine Causing Whooping Cough Outbreaks?
11. HCOs find risks & opportunities in quest for reduced costs & improved quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... for Telehealth, Inc. has received a three-year grant totaling $975,000, renewing its funding ... of Health and Human Services. , This funding marks, the fourth time the ...
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the leading provider of ... world, is excited to announce Andrew Ly as the winner of the LabRoots Summer ... costs. , Ly, who is in his third year at the University of ...
(Date:8/16/2017)... ... , ... With a new PD diagnosis every nine minutes, research is critical ... are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board ... in all areas relevant to PD research. The SAB meets annually to review ...
(Date:8/16/2017)... ... August 16, 2017 , ... Melbourne’s reign as the world’s most liveable city ... (EIU) annual Liveability Index. , The Index surveys 140 of the world’s cities and ... Melbourne has consistently come in the top three of the index. So what is ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve ... his tenure, Paul has served us in multiple leadership roles ... Pharmacy in Jun. 2015 and has provided decisive, strategic leadership ...
(Date:8/7/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... known U.S. mesh product liability claims and that it ... U.S. claims at reasonable values. Under the agreements, Endo ... of 2017 and continuing through the fourth quarter of ... the Company intends to increase its mesh product liability ...
(Date:8/4/2017)... 2017  Agragen, LLC, a Cincinnati ... biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces a ... drug candidates, AGR131.  This drug is designed to ... blood of patients suffering from inflammatory conditions such ... Biological pharmaceuticals ...
Breaking Medicine Technology: